Salivary metabolites are promising non‐invasive biomarkers of hepatocellular carcinoma and chronic liver disease
Liver Cancer International · 2021
DOI: 10.1002/lci2.25 ↗Kurz gefasst
Fachartikel in der Zeitschrift Liver Cancer International, 2021. Verfasst von Courtney E Hershberger und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, OH, USA. Die Arbeit wurde bisher 32-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NHLBI NIH HHS, NIAAA NIH HHS, NIDDK NIH HHS.
Abstract (Originalsprache)
Background Hepatocellular carcinoma (HCC) is a leading cause of cancer mortality worldwide. Improved tools are needed for detecting HCC so that treatment can begin as early as possible. Current diagnostic approaches and existing biomarkers, such as alpha‐fetoprotein (AFP) lack sensitivity, resulting in too many false negative diagnoses. Machine learning may be able to identify combinations of biomarkers that provide more robust predictions and improve sensitivity for detecting HCC. We sought to evaluate whether metabolites in patient saliva could distinguish those with HCC, cirrhosis, and those with no documented liver disease. Methods and Results We tested 125 salivary metabolites from 110 individuals (43 healthy, 37 HCC, 30 cirrhosis) and identified four metabolites that displayed significantly different abundance between groups (FDR P < .2). We also developed four tree‐based, machine‐learning models, optimized to include different numbers of metabolites, that were trained using cross‐validation on 99 patients and validated on a withheld test set of 11 patients. A model using 12 metabolites –octadecanol, acetophenone, lauric acid, 1‐monopalmitin, dodecanol, salicylaldehyde, glycyl‐proline, 1‐monostearin, creatinine, glutamine, serine and 4‐hydroxybutyric acid – had a cross‐validated sensitivity of 84.8%, specificity of 92.4% and correctly classified 90% of the HCC patients in the test cohort. This model outperformed previously reported sensitivities and specificities for AFP (20‐100 ng/mL) (61%, 86%) and AFP plus ultrasound (62%, 88%). Conclusions and Impact Metabolites detectable in saliva may represent products of disease pathology or a breakdown in liver function. Notably, combinations of salivary metabolites derived from machine learning may serve as promising non‐invasive biomarkers for the detection of HCC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Quantitative Health Sciences, Lerner Research Institute, Cleveland Clinic, OH, USA.
- Department of General Surgery, Cleveland Clinic, OH, USA.
- Department of Cardiovascular and Metabolic Sciences, Lerner Research Institute, Cleveland Clinic, OH, USA.
- Center for Microbiome and Human Health, Cleveland Clinic, OH, USA.
- Department of Pathology, Cleveland Clinic, OH, USA.
ORCID-Profile: Daniel M Rotroff
Förderung
- NHLBI NIH HHS
- NIAAA NIH HHS
- NIDDK NIH HHS
- National Institutes of Health
Zitieren
APA
Hershberger, C. E., Rodarte, A. I., Siddiqi, S., Moro, A., Acevedo-Moreno, L. A., Brown, J. M., Allende, D. S., Aucejo, F., & Rotroff, D. M. (2021). Salivary metabolites are promising non‐invasive biomarkers of hepatocellular carcinoma and chronic liver disease. Liver Cancer International. https://doi.org/10.1002/lci2.25
Vancouver
Hershberger CE, Rodarte AI, Siddiqi S, Moro A, Acevedo-Moreno LA, Brown JM, et al. Salivary metabolites are promising non‐invasive biomarkers of hepatocellular carcinoma and chronic liver disease. Liver Cancer International. 2021. doi:10.1002/lci2.25
BibTeX
@article{Hershberger2021,
author = {Hershberger, Courtney E and Rodarte, Alejandro I and Siddiqi, Shirin and Moro, Amika and Acevedo-Moreno, Lou-Anne and Brown, J Mark and Allende, Daniela S and Aucejo, Federico and Rotroff, Daniel M},
title = {Salivary metabolites are promising non‐invasive biomarkers of hepatocellular carcinoma and chronic liver disease},
journal = {Liver Cancer International},
year = {2021},
doi = {10.1002/lci2.25}
}
EUVIMED